HC Wainwright Forecasts FibroGen FY2026 Earnings

FibroGen, Inc. (NASDAQ:FGENFree Report) – Stock analysts at HC Wainwright issued their FY2026 earnings per share estimates for shares of FibroGen in a research note issued on Tuesday, December 17th. HC Wainwright analyst M. Keller forecasts that the biopharmaceutical company will earn ($0.56) per share for the year. HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for FibroGen’s FY2027 earnings at ($0.44) EPS and FY2028 earnings at ($0.44) EPS.

Other analysts have also issued reports about the stock. StockNews.com assumed coverage on shares of FibroGen in a research note on Monday. They issued a “hold” rating for the company. William Blair restated a “market perform” rating on shares of FibroGen in a report on Wednesday, November 13th.

Read Our Latest Analysis on FGEN

FibroGen Stock Performance

Shares of NASDAQ:FGEN opened at $0.34 on Wednesday. The firm has a market cap of $34.51 million, a price-to-earnings ratio of -0.28 and a beta of 0.82. The business has a 50-day simple moving average of $0.35 and a two-hundred day simple moving average of $0.57. FibroGen has a fifty-two week low of $0.18 and a fifty-two week high of $2.93.

FibroGen (NASDAQ:FGENGet Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.21. The business had revenue of $46.33 million during the quarter, compared to analysts’ expectations of $34.00 million. During the same quarter in the prior year, the firm earned ($0.52) EPS.

Institutional Trading of FibroGen

A number of hedge funds have recently bought and sold shares of FGEN. Geode Capital Management LLC grew its stake in shares of FibroGen by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock valued at $433,000 after purchasing an additional 32,884 shares during the period. Sei Investments Co. grew its position in FibroGen by 38.4% during the second quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 41,442 shares during the period. Point72 DIFC Ltd increased its holdings in FibroGen by 734.2% during the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 45,990 shares during the last quarter. Doheny Asset Management CA bought a new position in FibroGen in the second quarter worth approximately $48,000. Finally, FMR LLC raised its position in FibroGen by 21.8% in the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 68,569 shares during the period. Hedge funds and other institutional investors own 72.71% of the company’s stock.

About FibroGen

(Get Free Report)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.

Featured Stories

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.